Median PFS Approaches 14 Months! 3SBio's PD-1/VEGF Bispecific Antibody Posts Impressive Data at ESMO 2026
SHANGHAI, Oct. 28, 2026 /PRNewswire/ -- At the 2026 European Society for Medical Oncology (ESMO) Congress, 3SBio presented long-term follow-up results from a Chinese Phase II clinical study of SSGJ-707 combined with chemotherapy as a first-line...